CaroGen’s CARG-2020 Preclinical Data on Ovarian Cancer Immunotherapy to be Presented Orally at the Society of Gynecologic Oncology Annual Meeting

CaroGen Management to Speak at The World Vaccine Immunotherapy Congress

Farmington, CT, September 5, 2022– CaroGen Corporation (, a developer of trans-formative immunotherapies for cancer and infectious diseases, today announced that Bijan Almassian, PhD, President & CEO, and Timur Yarovinsky, MD, PhD, Vice President of Discovery

Bijan Almassian, PhD. on LinkedIn: CaroGen in pact with NIH to develop flu vaccine – BioCT | 21 comments

We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine.

“Relational Contract” Supports Outsourcing Of Hepatitis B Immunotherapy

Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide chronically infected with hepatitis B virus (HBV). Currently there is no cure for HBV.

CaroGen and Wayne State University scientists report significant progress on development of CARG-2020 for the potential treatment of ovarian cancer

Farmington, Conn., Oct. 25, 2020 – Privately-held CaroGen Corp., in collaboration with a team of scientists at the C.S. Mott Center for Human Growth and Development at Wayne State University.

UConn Health, CaroGen Collaborate on Promising Technology for Colorectal Cancer Treatment

UConn Health researchers, along with industry partners, have developed a promising potential candidate for treating colorectal cancer.

Hepatitis B “Functional Cure” On The Way? A CDMO Helps Out

Great to have an interview with Louis Garguilo, Chief Editor, Outsourced Pharma regarding to one of our lead products, CARG-201 for potential functional cure of patients chronically infected with HBV.

2021 Tech 25: CaroGen targets breakthrough immunotherapy drug

Very honored to be selected by Hartford Business Journal as one of top 25 technology companies in state of Connecticut. We develop breakthrough immunotherapies and vaccines for cancer and infectious diseases.

CaroGen Corporation CaroGen Corporation (203) 815-5782